Tango Therapeutics, Inc. (TNGX) · Aug 11, 2026 · Share issuance

ATM capacity jumps to $400M, expanding funding but dilution risk

$400M ATM authorization — New ATM capacity of $400M, including $35.6M carried over; ~$364.4M incremental capacity

ATM capacity jumps to $400M, expanding funding but dilution risk

The key change is a much larger equity-financing tool. Tango replaces its prior $100.0M ATM program with a new prospectus supplement permitting up to $400.0M of stock sales, rather than merely extending the existing program (Other Events). The practical increase in unused capacity is approximately $364.4M, because $35.6M of the old program was still available and rolls into the new one (Other Events).

Financing detailFiling figure
Prior ATM authorization$100.0M (Other Events)
Shares sold under prior ATM$64.4M (Other Events)
Unsold prior capacity carried forward$35.6M (Other Events)
New total ATM capacity$400.0M (Other Events)
Approximate incremental capacity$364.4M (calculated from Other Events)

This is not an immediate capital raise. The company has authorized the ability to sell up to $400.0M of stock through the market, but the filing does not disclose a new sale, proceeds received, pricing, or a timetable for issuance. The near-term financial impact is therefore prospective rather than an immediate cash infusion.

Versus the prior standing expectation, the financing overhang is materially larger. Investors already knew Tango had an ATM program and roughly $35.6M of remaining capacity; the surprise is the expansion to $400.0M. That improves access to cash but also creates substantially more potential dilution than the previously disclosed program, making the net read mildly negative absent evidence that the capital is urgently needed or will fund value-creating milestones.

The filing changes financing flexibility, not the operating outlook. It contains no new clinical data, partnership terms, guidance, cash-runway update, or financial results. The main information is the expanded ability to issue equity, with actual dilution dependent on whether and when Tango uses the ATM (Other Events).

Original filing on SEC EDGAR

More Tango Therapeutics, Inc. news

ATM capacity jumps to $400M, expanding funding but dilution risk | TNGX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.